Physician profile
Amy Sood Barshinger
NPI 1548455256
$2,814.08
in general payments reported to CMS, 2019-2025
20 companies · $552 in 2025
The $552 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $388 · 2023: $909 · 2024: $824 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.98 |
| Education | $118.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $624.79 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $460.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $268.00 | 2021-2025 | |
| Novo Nordisk INC | $238.88 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $229.15 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $182.97 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.94 | 2022-2024 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $125.13 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $116.69 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $95.40 | 2023 | Pomalyst |
| Phathom Pharmaceuticals, INC. | $61.43 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $57.51 | 2024-2025 | |
| Ibsa Pharma INC. | $34.84 | 2024 | Tirosint, Licart |
| Abbott Laboratories | $24.76 | 2022 | |
| Abbvie INC. | $23.92 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.23 | 2023 | Inpen Smart Insulin Delivery System |
| Verona Pharma, INC. | $18.41 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $18.10 | 2024 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $17.59 | 2022 | |
| Tactile Systems Technology INC | $17.03 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sood Barshinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.